Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corp (NYSE: ENOV) delivers innovative medical technologies focused on orthopedic care and musculoskeletal health. This news hub provides investors and industry professionals with timely updates on the company's strategic developments, product advancements, and market positioning.
Access comprehensive coverage of Enovis' latest press releases, including earnings reports, regulatory milestones, partnership announcements, and clinical innovations. The curated collection serves as a centralized resource for tracking the company's progress in prevention & recovery solutions and reconstructive medical devices.
Key areas of focus include surgical technology advancements, FDA clearances, research collaborations, and operational updates across Enovis' Prevention & Recovery and Reconstructive segments. Users gain insights into how the company addresses evolving healthcare demands through its clinically validated products.
Bookmark this page for streamlined access to Enovis' official communications and analysis of its role in shaping orthopedic treatment standards. Stay informed about developments impacting long-term growth in the medical technology sector.
Enovis™ (NYSE: ENOV) has launched the AltiVate Reverse® Glenoid System, enhancing its market-leading AltiVate Reverse line. This new system, which received FDA 510(k) clearance in May 2024, offers modular, augmented baseplates and bone-sparing options, aiming to broaden the range of patients suitable for reverse shoulder arthroplasty. The first surgery using this system was performed by Dr. Mark Frankle at Tampa General Hospital on July 8, 2024. The system includes neutral and 15° wedge options, various central compression screw lengths, and four new glenospheres to optimize patient outcomes. Reverse shoulder arthroplasty accounts for over 60% of the 200,000+ annual shoulder replacements in the U.S., highlighting the growing demand for versatile implants. Enovis continues to prioritize surgeon-driven innovation and patient care through its comprehensive and efficient solutions.
Enovis (ENOV) will participate in upcoming investor conferences with its management team. Ben Berry, CFO, will be at the Bank of America Healthcare Conference on May 15th, and CEO Matt Trerotola will be at the William Blair Growth Stock Conference on June 4th. The webcasts and replays will be accessible on the Company's website.
Enovis (NYSE: ENOV) announced strong first-quarter 2024 financial results with a 27% sales growth on a reported basis, net sales of $516 million, and adjusted EBITDA of $83 million. The company reported a net loss of $1.32 per share but adjusted earnings per diluted share of $0.50. Enovis highlighted the acquisition of Lima, new product launches, and an improved 2024 financial outlook.
FAQ
What is the current stock price of Enovis (ENOV)?
What is the market cap of Enovis (ENOV)?
